Login to Your Account

Alizyme Kills Renzapride After Phase III Failure

By Nuala Moran

Wednesday, April 30, 2008
LONDON - Alizyme plc axed its Phase III irritable bowel syndrome treatment Renzapride following a 1,800 patient study that showed statistical significance on the primary endpoint but was confounded by a high level of placebo response. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription